TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AdAlta Ltd. ( (AU:1AD) ) has shared an update.
AdAlta Ltd. announced the quotation of 388,666,666 fully paid ordinary securities and 194,333,333 options expiring in June 2028 on the ASX. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning and providing opportunities for stakeholders.
The most recent analyst rating on (AU:1AD) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Ltd. operates in the biotechnology industry, focusing on the development of innovative therapeutic products. The company is known for its proprietary i-body technology, which is designed to address challenging diseases with unmet medical needs.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.62M
For detailed information about 1AD stock, go to TipRanks’ Stock Analysis page.